Tech Company M&A Transactions
Taligen Therapeutics Acquisition
Operating out of Aurora, Taligen Therapeutics was purchased by Alexion Pharmaceuticals. The companies indicated that total deal value was $111 million.
Transaction Overview
Company Name
Acquired By
Announced On
1/31/2011
Transaction Type
M&A
Amount
$111,000,000
M&A Terms
The acquisition was completed with an upfront cash payment of $111 million for 100 percent of Taligen's equity interests. Additional contingent payments would be earned upon reaching various clinical efficacy and product approval milestones in both the US and European Union for up to six products.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
12635 East Montview Blvd 223
Aurora, CO 80045
USA
Aurora, CO 80045
USA
Phone
Website
Email Address
Overview
Taligen's lead technology is directed at inhibiting factor B, an essential component in the amplification of complement activation. Inhibition of factor B down-regulates complement activation, thereby dampening the inflammatory response.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Abbie Celniker
Chief Scientific Officer
Michael Holers
President
Woodruff Emlen
Browse more venture capital transactions:
Prev: 1/31/2011: ReachForce venture capital transaction
Next: 1/31/2011: LibreDigital venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs